Advanced Neuromodulation (NASDAQ:ANSI)
Historical Stock Chart
From Sep 2019 to Sep 2024
ANS' Newest Lead, Lamitrode Tripole 8, Allows Precision in Pain
Treatment
Unique Design Provides Greater Accuracy and Control to Enhance the Performance
of ANS Spinal Cord Stimulators
PLANO, Texas, Nov. 22 /PRNewswire-FirstCall/ -- Advanced Neuromodulation
Systems, Inc. (NASDAQ:ANSI) (ANS) today introduced the Lamitrode(R) Tripole 8
lead, a significant addition to its growing family of leads. The first of its
kind on the market, this innovative surgical lead features a three-column
electrode array, which allows clinicians to direct the stimulation current more
precisely to nerve structures deep in the spinal cord.
"We designed the Tripole 8 to facilitate precise delivery of stimulation to the
low back area," said Claudio A. Feler, M.D. and designer of the new lead. "The
resulting improved coverage is intended to help physicians enhance therapy for
their patients."
The six independently controlled midline contacts and optional anodal guards
(lateral contacts used as a single anode) give the Tripole 8 lead a tremendous
amount of programming flexibility. The tripolar configuration is designed to
allow the electrical field to be steered longitudinally along the lead and
laterally across the lead array when used in conjunction with the ANS propriety
MultiStim(R) technology. This "steerability" helps to confine the stimulation
field between electrodes, making it possible for clinicians to more effectively
target the back fibers that cause pain and to provide a broader area of
stimulation coverage.
"The Lamitrode(R) Tripole 8 lead is another example of our cooperative efforts
with renowned physicians to develop cutting-edge neurostimulation technology --
a top priority for ANS, as we strive to create superior products that address
significant clinical needs," said ANS President and CEO Chris Chavez.
About chronic pain
Chronic pain affects an estimated 50 million Americans, of whom more than half
are partially or totally disabled. At present, approximately $100 billion are
spent in the U.S. on the diagnosis and treatment of chronic pain, which
represents the most common indication for spinal cord stimulation therapy. The
106th U.S. Congress has declared this the "Decade of Pain Control and
Research," helping to bring spinal cord stimulation to the forefront as a
viable and effective option in the treatment of chronic pain.
About Advanced Neuromodulation Systems (ANS)
Advanced Neuromodulation Systems, Inc. designs, develops, manufactures and
markets implantable systems used to manage chronic intractable pain and other
disorders of the central nervous system. A technology leader in the
neuromodulation industry, ANS offers a family of proprietary neurostimulation
devices and implantable drug pumps for an expanding range of therapeutic
applications. ANS was recently named among FORTUNE's 100 Fastest Growing
Companies and has been recognized among Forbes' 200 Best Small Companies for
two consecutive years. Frost & Sullivan also recently honored the company with
its Product Innovation Award. Additional information is available at
http://www.ans-medical.com/ .
DATASOURCE: Advanced Neuromodulation Systems, Inc.
CONTACT: Stephanie Coggin, +1-972-716-0500 x 17, or
, for Advanced Neuromodulation Systems, Inc.
Web site: http://www.ans-medical.com/